Target intelligence / Profile preview

Myc-associated zinc finger protein (MAZ)

Target
MAZ
Molecular classification
Transcription factor, Zinc finger protein (C2H2-type), Chromatin organization protein
01

Overview

Myc-associated zinc finger protein (MAZ) is a widely expressed C2H2-type zinc finger transcription factor that binds specific DNA motifs (notably purine-rich sites), often near MYC and other critical gene promoters. MAZ regulates transcriptional initiation and termination, and functions as a chromatin organizer, acting both independently and in concert with the insulator protein CTCF to influence chromatin domain boundaries and genome architecture. MAZ is directly involved in controlling the transcription of immune response genes, in part by facilitating the binding of interferon-stimulated transcription factors (such as STAT1) and modifying chromatin accessibility. Its dysregulation or mutation is associated with several cancers, amyloidosis, and certain developmental syndromes, establishing its importance in normal physiology and disease. MAZ does not appear to have any currently approved drugs directly targeting it, but its central role in transcriptional programs makes it a potential therapeutic target in oncology and immunology.

Other names
Myc-associated zinc finger proteinMAZZNF801MAZISAF-1ZF87Pur-1Purine-binding transcription factorSerum amyloid A-activating factor-1Transcription factor Zif87Zinc finger protein 801PUR1SAF-2SAF-3Zif87zinc-finger protein, 87 kilodaltons
02

Mechanism of action

Drugs (if any) would likely modulate MAZ transcriptional activity or its interaction with DNA or chromatin-associated factors, potentially influencing immune or oncogenic transcriptional programs

03

Biological functions

Regulation of gene transcriptionChromatin domain insulationGenome organizationRegulation of immune response genesRNA polymerase II pausingAlternative RNA splicing
04

Disease associations

Cancer (glioblastoma, breast cancer, prostate cancer, liposarcoma)AmyloidosisVon Hippel–Lindau syndromeSpondylocostal dysostosis 5Colitis/colon cancer (inflammatory roles)
05

Safety considerations

Potential for widespread gene expression changes if targeted systemicallyRisk of developmental, hematopoietic, or ocular abnormalities due to roles in differentiation and organogenesis
06

Biomarkers

Changes in MAZ expression or activity could serve as biomarkers in cancers or diseases associated with immune dysregulation

Beyond the preview

Go deeper on Myc-associated zinc finger protein (MAZ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myc-associated zinc finger protein (MAZ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call